

# Silvia Stacchiotti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3229958/publications.pdf>

Version: 2024-02-01

246  
papers

15,157  
citations

13827

67  
h-index

22102

113  
g-index

246  
all docs

246  
docs citations

246  
times ranked

10350  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>CINSARC</scp> in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <scp>ISGâ€‘ETS</scp> 1001 study. <i>Cancer Medicine</i> , 2023, 12, 1350-1357.	1.3	7
2	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculatorâ€‘based risk stratification analysis of the ISGâ€‘ETS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
3	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 3274-3286.	0.7	5
4	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective caseâ€‘series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	2.0	5
5	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	0.5	10
6	A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4027-4032.	3.2	21
7	Effect of Mild and Moderate Hepatic Impairment (Defined by Childâ€‘Pugh Classification and National) Tj ETQq1 1 0.784314 rgBT /Over Journal of Clinical Pharmacology, 2022, 62, 992-1005.	1.0	3
8	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
9	Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 491-503.	1.1	8
10	Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. <i>Hpb</i> , 2022, 24, 1688-1696.	0.1	5
11	Firstâ€‘line chemotherapy in advanced intraâ€‘abdominal wellâ€‘differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	2.0	3
12	Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. <i>Cancers</i> , 2022, 14, 2624.	1.7	1
13	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	1.3	4
14	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	0.7	13
15	Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 1142-1150.	0.7	23
16	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 480-492.	1.0	8
17	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	1.9	9
18	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021, 26, e863-e873.	1.9	28

#	ARTICLE	IF	CITATIONS
19	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021, 127, 884-893.	2.0	29
20	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network. <i>Cancer</i> , 2021, 127, 569-576.	2.0	24
21	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4706-4717.	0.7	16
22	Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas. <i>Oncology</i> , 2021, 99, 3-7.	0.9	3
23	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 83.	3.5	11
24	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
25	Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. <i>Future Oncology</i> , 2021, 17, 1253-1263.	1.1	17
26	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
27	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	0.7	105
28	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 493-499.	1.2	13
29	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. <i>Cancer Medicine</i> , 2021, 10, 4356-4365.	1.3	6
30	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65
31	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STs 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	1.9	2
32	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1422-1432.	1.3	7
33	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	1.3	8
34	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	1.3	26
35	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. <i>Cancers</i> , 2021, 13, 6057.	1.7	9
36	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. <i>Modern Pathology</i> , 2020, 33, 217-227.	2.9	15

#	ARTICLE	IF	CITATIONS
37	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	2.0	25
38	Worsening Hemoptysis in a Rare Intrapulmonary Triton Tumor Mimicking Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, e199-e201.	0.7	1
39	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	1.9	6
40	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	2.0	22
41	Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management. <i>Cancers</i> , 2020, 12, 2703.	1.7	27
42	In Reply. <i>Oncologist</i> , 2020, 25, e2018.	1.9	0
43	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1423-1432.	5.1	194
44	Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review. <i>ESMO Open</i> , 2020, 5, e000663.	2.0	15
45	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85
46	Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. <i>Cancer</i> , 2020, 126, 4615-4616.	2.0	0
47	ASO Author Reflections: Extraskeletal Myxoid Chondrosarcoma: A Rare Sarcoma Associated With Prolonged Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 797-798.	0.7	0
48	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISC), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
49	Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 571-576.	1.3	6
50	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	2.0	11
51	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
52	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
53	Reply to Incidence of extrameningeal solitary fibrous tumors and Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy. <i>Cancer</i> , 2020, 126, 4069-4070.	2.0	0
54	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466.	5.1	51

#	ARTICLE	IF	CITATIONS
55	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Review of Anticancer Therapy, 2020, 20, 15-28.	1.1	6
56	The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. European Journal of Surgical Oncology, 2020, 46, 1320-1326.	0.5	17
57	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. Cancer, 2020, 126, 3002-3012.	2.0	39
58	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. European Journal of Cancer, 2020, 127, 96-107.	1.3	243
59	Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis. Journal of Surgical Oncology, 2019, 119, 318-323.	0.8	9
60	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncoimmunology, 2019, 8, e1617588.	2.1	41
61	Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. Annals of Surgical Oncology, 2019, 26, 3535-3541.	0.7	10
62	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1252-1262.	5.1	57
63	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. Cancers, 2019, 11, 1015.	1.7	21
64	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. European Journal of Cancer, 2019, 109, 51-60.	1.3	134
65	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	6.3	273
66	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical Cancer Research, 2019, 25, 5295-5300.	3.2	70
67	Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice. Lancet Oncology, The, 2019, 20, 901-903.	5.1	0
68	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 877-886.	5.1	75
69	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. Journal of Pathology, 2019, 249, 90-101.	2.1	27
70	Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 547-556.	0.9	22
71	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. EClinicalMedicine, 2019, 17, 100215.	3.2	42
72	Chordoma: update on disease, epidemiology, biology and medical therapies. Current Opinion in Oncology, 2019, 31, 114-120.	1.1	70

#	ARTICLE	IF	CITATIONS
73	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 1309-1318.	1.4	30
74	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144.	5.1	97
75	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. <i>European Journal of Cancer</i> , 2019, 106, 225-233.	1.3	32
76	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11003-11003.	0.8	50
77	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11042-11042.	0.8	4
78	Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18236-e18236.	0.8	1
79	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36.	1.3	49
80	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 10101 trial). <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 431-441.	5.2	134
81	Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor. <i>Anti-Cancer Drugs</i> , 2018, 29, 589-595.	0.7	10
82	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone " Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	0.5	70
83	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
84	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 "CREATE"™. <i>Annals of Oncology</i> , 2018, 29, 758-765.	0.6	67
85	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	5.1	81
86	Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 603-613.	1.9	63
87	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	1.9	27
88	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	1.9	62
89	Synovial Sarcoma: Current Concepts and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2018, 36, 180-187.	0.8	129
90	Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	0.9	19

#	ARTICLE	IF	CITATIONS
91	The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelialâ€“mesenchymal transition, and immune response. <i>Cancer Communications</i> , 2018, 38, 1-14.	3.7	25
92	Bone sarcomas: ESMOâ€“PaedCanâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
93	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. <i>European Journal of Cancer</i> , 2018, 105, 19-27.	1.3	56
94	Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. <i>Frontiers in Oncology</i> , 2018, 8, 449.	1.3	39
95	Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. <i>Cancer</i> , 2018, 124, 4056-4063.	2.0	40
96	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
97	Gastrointestinal stromal tumours: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
98	Soft tissue and visceral sarcomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
99	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	1.8	4
100	Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1226-1233.	0.4	39
101	Novel intraâ€“genic large deletions of <i>CTNNB1</i> gene identified in WT desmoidâ€“type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 495-503.	1.5	18
102	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11502-11502.	0.8	16
103	IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypesâ€“Results of the phase I part.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11515-11515.	0.8	8
104	Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11518-11518.	0.8	5
105	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11534-11534.	0.8	1
106	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11560-11560.	0.8	2
107	Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant versus 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10vr median FU.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11558-11558.	0.8	0
108	Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11561-11561.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 11540-11540.	0.8	1
110	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. Molecular Cancer Research, 2017, 15, 553-562.	1.5	53
111	Pharmacological therapies for Liposarcoma. Expert Review of Clinical Pharmacology, 2017, 10, 361-377.	1.3	17
112	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European Journal of Cancer, 2017, 76, 84-92.	1.3	26
113	Neoadjuvant treatment: a novel standard?. Current Opinion in Oncology, 2017, 29, 253-259.	1.1	10
114	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	5.1	370
115	Review of past and present clinical cases with a view to future treatment options. Future Oncology, 2017, 13, 11-28.	1.1	4
116	β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Molecular Oncology, 2017, 11, 1495-1507.	2.1	28
117	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Cancer Journal (Sudbury, Mass ), 2017, 23, 86-91.	1.0	71
118	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Annals of Oncology, 2017, 28, 1230-1242.	0.6	168
119	<sc>HSPA</sc>8 as a novel fusion partner of <sc>NR</sc>4<sc>A</sc>3 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes and Cancer, 2017, 56, 582-586.	1.5	38
120	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 â€œCREATEâ€™. Annals of Oncology, 2017, 28, 3000-3008.	0.6	70
121	Establishment and genomic characterization of the new chordoma cell line Chor-IN-1. Scientific Reports, 2017, 7, 9226.	1.6	14
122	Medical treatment of advanced chordomas. European Journal of Cancer, 2017, 83, 220-228.	1.3	45
123	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. British Journal of Cancer, 2017, 117, 340-346.	2.9	20
124	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology, 2017, 28, 2399-2408.	0.6	274
125	Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Medicine, 2017, 15, 109.	2.3	71
126	How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clinical Sarcoma Research, 2017, 7, 4.	2.3	6



#	ARTICLE	IF	CITATIONS
127	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017, 56, 88-92.	0.8	146
128	(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. <i>European Journal of Cancer</i> , 2017, 70, 1-11.	1.3	37
129	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. <i>Journal of Investigative Dermatology</i> , 2017, 137, 484-493.	0.3	29
130	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. <i>Sarcoma</i> , 2017, 2017, 1-5.	0.7	6
131	Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. <i>BMC Medicine</i> , 2017, 15, 160.	2.3	4
132	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017, 8, 60036-60045.	0.8	17
133	Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11003-11003.	0.8	3
134	Neoadjuvant denosumab treatment of locally advanced giant cell tumor of bone (GCTB).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11026-11026.	0.8	2
135	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11057-11057.	0.8	36
136	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11058-11058.	0.8	21
137	International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11062-11062.	0.8	3
138	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11065-11065.	0.8	2
139	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11081-TPS11081.	0.8	5
140	New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs). <i>Oncotarget</i> , 2017, 8, 32492-32504.	0.8	14
141	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. <i>Spine</i> , 2016, 41, 1049-1057.	1.0	74
142	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	5.1	318
143	Epithelioid angiosarcoma of the thyroid gland without distant metastases at diagnosis: report of six cases with a long follow-up. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 223-232.	1.4	19
144	The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 473-484.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelialâ€“Mesenchymal Transitionâ€“like Process and 22q Loss. <i>Molecular Cancer Research</i> , 2016, 14, 820-829.	1.5	25
146	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
147	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	0.7	136
148	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	0.7	56
149	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	0.6	90
150	Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review. <i>Clinical Sarcoma Research</i> , 2016, 6, 16.	2.3	5
151	Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. <i>Surgical Oncology</i> , 2016, 25, 125-131.	0.8	41
152	Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2016, 21, 361-369.	0.3	16
153	Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1064-1070.	0.5	86
154	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€“Soft Tissue and Bone Sarcoma Group (EORTCâ€“STBSC) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	1.3	99
155	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	3.2	78
156	A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11018-11018.	0.8	4
157	Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11042-11042.	0.8	2
158	Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-up of an exploratory analysis on a phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11044-11044.	0.8	1
159	Sunitinib (SM) in advanced extraskeletal myxoid chondrosarcoma (EMC): Updated analysis in 11 patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11059-11059.	0.8	1
160	Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours. <i>Oncotarget</i> , 2016, 7, 45015-45026.	0.8	13
161	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11045-11045.	0.8	0
162	Solitary fibrous tumour relapsing with a single bone metastasis: Report of five cases.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22525-e22525.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.. Journal of Clinical Oncology, 2016, 34, 11062-11062.	0.8	0
164	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. American Journal of Surgical Pathology, 2015, 39, 383-393.	2.1	101
165	Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Modern Pathology, 2015, 28, 1074-1083.	2.9	67
166	Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. European Journal of Cancer, 2015, 51, 186-192.	1.3	133
167	Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncology, The, 2015, 16, e71-e83.	5.1	367
168	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. Annals of Surgical Oncology, 2015, 22, 1447-1454.	0.7	152
169	Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer, 2015, 15, 58.	1.1	14
170	Response of conventional chondrosarcoma to gemcitabine alone: a case report. Clinical Sarcoma Research, 2015, 5, 9.	2.3	7
171	Imatinib in advanced chordoma: A retrospective case series analysis. European Journal of Cancer, 2015, 51, 2609-2614.	1.3	78
172	Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. European Journal of Cancer, 2015, 51, 2800-2807.	1.3	58
173	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. European Journal of Cancer, 2015, 51, 210-217.	1.3	97
174	Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final update after the closure of the named use program.. Journal of Clinical Oncology, 2015, 33, 10562-10562.	0.8	3
175	Natural history and outcome in a large series of primary dermatofibrosarcoma protuberans (DFSP) treated at a reference institution.. Journal of Clinical Oncology, 2015, 33, 10554-10554.	0.8	0
176	Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile.. Journal of Clinical Oncology, 2015, 33, 10553-10553.	0.8	1
177	Abstract 1086: CTNNB1-mutated desmoid tumors have different gene expression patterns compared to wild-type ones. , 2015, , .		0
178	Abstract 74: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1. , 2015, , .		0
179	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. British Journal of Cancer, 2014, 111, 1350-1362.	2.9	21
180	Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. European Journal of Surgical Oncology, 2014, 40, 1662-1670.	0.5	36

#	ARTICLE	IF	CITATIONS
181	Emerging therapies for adult soft tissue sarcoma. Expert Review of Anticancer Therapy, 2014, 14, 689-704.	1.1	49
182	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. Neuro-Oncology, 2014, 16, 72-80.	0.6	13
183	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. Molecular Cancer Therapeutics, 2014, 13, 249-259.	1.9	30
184	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii113-iii123.	0.6	212
185	Activity of sunitinib in extraskeletal myxoid chondrosarcoma. European Journal of Cancer, 2014, 50, 1657-1664.	1.3	74
186	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. European Journal of Cancer, 2014, 50, 3021-3028.	1.3	50
187	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. European Journal of Cancer, 2014, 50, 784-792.	1.3	80
188	Extraskeletal myxoid chondrosarcoma: A retrospective analysis of 69 patients with localized disease and molecularly confirmed diagnosis.. Journal of Clinical Oncology, 2014, 32, 10589-10589.	0.8	2
189	Activity of chemotherapy in a series of patients with locally advanced or metastatic pleomorphic rhabdomyosarcoma: A retrospective analysis.. Journal of Clinical Oncology, 2014, 32, 10592-10592.	0.8	0
190	Malignancy grade and immunohistochemical myogenic/rhabdomyoblastic differentiation as an outcome determinant in retroperitoneal liposarcoma.. Journal of Clinical Oncology, 2014, 32, 10588-10588.	0.8	0
191	Primary epithelioid angiosarcoma.. Journal of Clinical Oncology, 2014, 32, 10578-10578.	0.8	0
192	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clinical Sarcoma Research, 2013, 3, 8.	2.3	38
193	Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. Clinical Sarcoma Research, 2013, 3, 4.	2.3	81
194	Localised thoracic sarcomas: Outcome improvement over time at a single institution. European Journal of Cancer, 2013, 49, 2689-2697.	1.3	16
195	Targeted Therapies in Rare Sarcomas. Hematology/Oncology Clinics of North America, 2013, 27, 1049-1061.	0.9	18
196	Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. Journal of Translational Medicine, 2013, 11, 237.	1.8	6
197	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clinical Sarcoma Research, 2013, 3, 16.	2.3	34
198	Response to chemotherapy of solitary fibrous tumour: A retrospective study. European Journal of Cancer, 2013, 49, 2376-2383.	1.3	77

#	ARTICLE	IF	CITATIONS
199	Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. <i>Annals of Oncology</i> , 2013, 24, 2181-2189.	0.6	63
200	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823.	0.6	69
201	Phase II study on lapatinib in advanced EGFR-positive chordoma. <i>Annals of Oncology</i> , 2013, 24, 1931-1936.	0.6	122
202	Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-À-vis Temozolomide and Antiangiogenics. <i>Clinical Cancer Research</i> , 2013, 19, 5192-5201.	3.2	67
203	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10516-10516.	0.8	8
204	Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. <i>Annals of Oncology</i> , 2012, 23, 501-508.	0.6	130
205	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	0.6	180
206	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	0.8	156
207	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	0.8	230
208	Sunitinib malate in solitary fibrous tumor (SFT). <i>Annals of Oncology</i> , 2012, 23, 3171-3179.	0.6	140
209	High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1202-1215.	2.1	91
210	Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. <i>Clinical Sarcoma Research</i> , 2012, 2, 22.	2.3	27
211	Leiomyosarcoma and sarcoma with myogenic differentiation. <i>Cancer</i> , 2012, 118, 5349-5357.	2.0	3
212	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	2.0	85
213	Receptor tyrosine kinase pathway analysis sheds light on similarities between clear cell sarcoma and metastatic melanoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 111-126.	1.5	22
214	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	2.0	222
215	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10006-10006.	0.8	3
216	Systemic Therapy Options for Unresectable and Metastatic Chordomas. <i>Current Oncology Reports</i> , 2011, 13, 323-330.	1.8	42

#	ARTICLE	IF	CITATIONS
217	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor $\alpha$ or $\beta$ . <i>Cancer</i> , 2011, 117, 826-831.	2.0	42
218	Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. <i>International Journal of Cancer</i> , 2011, 128, 983-990.	2.3	18
219	Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. <i>International Journal of Cancer</i> , 2011, 129, 1761-1772.	2.3	68
220	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	0.6	42
221	Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. <i>Annals of Oncology</i> , 2011, 22, 1682-1690.	0.6	185
222	Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution. <i>Annals of Surgery</i> , 2010, 251, 506-511.	2.1	253
223	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. <i>Annals of Surgical Oncology</i> , 2010, 17, 211-219.	0.7	159
224	Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	2.0	93
225	Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1286-1297.	1.9	83
226	Tumor response to sunitinib malate observed in clear-cell sarcoma. <i>Annals of Oncology</i> , 2010, 21, 1130-1131.	0.6	37
227	Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. <i>Neuro-Oncology</i> , 2010, 12, 776-789.	0.6	88
228	Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution. <i>Annals of Surgical Oncology</i> , 2010, 17, 3229-3233.	0.7	87
229	Response to imatinib plus sirolimus in advanced chordoma. <i>Annals of Oncology</i> , 2009, 20, 1886-1894.	0.6	142
230	Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma. <i>Clinical Cancer Research</i> , 2009, 15, 1096-1104.	3.2	138
231	High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment—Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. <i>Radiology</i> , 2009, 251, 447-456.	3.6	198
232	Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). <i>European Journal of Surgical Oncology</i> , 2009, 35, 739-745.	0.5	156
233	Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 24-30.	0.8	410
234	Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. <i>British Journal of Cancer</i> , 2007, 96, 180-181.	2.9	22

#	ARTICLE	IF	CITATIONS
235	Chordoma. <i>Current Opinion in Oncology</i> , 2007, 19, 367-370.	1.1	144
236	Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. <i>European Journal of Cancer</i> , 2007, 43, 601-606.	1.3	44
237	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	5.1	416
238	Myxoid/round cell and pleomorphic liposarcomas. <i>Cancer</i> , 2007, 109, 2522-2531.	2.0	145
239	Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. <i>Journal of Pathology</i> , 2007, 212, 227-235.	2.1	37
240	Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2007, 49, 864-866.	0.8	36
241	Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 1484-1490.	1.3	85
242	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	3.2	135
243	Imatinib mesylate in chordoma. <i>Cancer</i> , 2004, 101, 2086-2097.	2.0	250
244	Confusion after antibiotics. <i>Lancet</i> , The, 2001, 357, 1410.	6.3	23
245	The Impact of Chemotherapy on Survival of Patients with Extremity and Trunk Wall Soft Tissue Sarcoma: Revisiting the Results of the EORTC-STBSG 62931 Randomised Trial Using Sarculator, a Validated Nomogram-Based Risk Assessment Tool. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
246	Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1